Nanotechnology Chemotherapy for Pancreatic Cancer
Join our Phase I/II personalized neoantigen vaccine trial for advanced solid tumors. Custom vaccines designed from your tumor’s genetics to fight cancer.
A Phase III Randomized Trial of Nanotechnology-Delivered Chemotherapy vs. Standard Care in Pancreatic Cancer
Full Title
A randomized, open-label, multicenter phase III study comparing nanoparticle-encapsulated chemotherapy delivery versus standard FOLFIRINOX in patients with newly diagnosed metastatic pancreatic adenocarcinoma
Purpose
This study tests whether using tiny nanoparticles to deliver chemotherapy drugs directly to pancreatic cancer cells works better than standard chemotherapy. The nanoparticles act like guided missiles, carrying drugs specifically to cancer cells while avoiding healthy cells.
Primary Objectives
- Compare overall survival between nanoparticle-delivered chemotherapy and standard FOLFIRINOX
- Evaluate progression-free survival and objective response rates
- Assess safety profile and quality of life measures
Diseases
- Pancreatic Cancer
- Metastatic Pancreatic Adenocarcinoma
Who Can Join this Trial
To participate in this study, you must meet ALL of the following criteria
- Have histologically confirmed metastatic pancreatic ductal adenocarcinoma
- Have newly diagnosed metastatic disease with no prior systemic therapy
- Have at least one measurable lesion per RECIST v1.1 criteria
- ECOG performance status 0-1
- Age 18-75 years
- Life expectancy ≥12 weeks
- Adequate organ function including blood counts, liver, and kidney function
- No significant cardiac disease
- Ability to tolerate IV contrast for imaging studies
Access Clinical Trials
Locations
CONTACT
📞 Call Now: 1-800-NEOVITA (1-800-636-8482)
🌐 Online Scheduling: Schedule Your Consultation
📧 Email: info@neovitaoncology.com